Статті в журналах з теми "Ataluren"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Ataluren".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Michorowska, Sylwia. "Ataluren—Promising Therapeutic Premature Termination Codon Readthrough Frontrunner." Pharmaceuticals 14, no. 8 (August 9, 2021): 785. http://dx.doi.org/10.3390/ph14080785.
Повний текст джерелаDavies, S., N. Serradell, E. Rosa, and R. Castañer. "Ataluren." Drugs of the Future 33, no. 9 (2008): 733. http://dx.doi.org/10.1358/dof.2008.033.09.1252090.
Повний текст джерелаMercuri, Eugenio, Francesco Muntoni, Andrés Nascimento Osorio, Már Tulinius, Filippo Buccella, Lauren P. Morgenroth, Heather Gordish-Dressman, et al. "Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study." Journal of Comparative Effectiveness Research 9, no. 5 (April 2020): 341–60. http://dx.doi.org/10.2217/cer-2019-0171.
Повний текст джерелаKaushik, Diksha, Jiyuan Ma, Guodong Gu, Seongwoo Hwang, Young-Choon Moon, and Ronald Kong. "LC–MS/MS quantification of ataluren and ataluren acyl glucuronide in human plasma/urine: application in clinical studies." Bioanalysis 12, no. 21 (November 2020): 1545–55. http://dx.doi.org/10.4155/bio-2020-0214.
Повний текст джерелаMcDonald, CM, K. Bushby, M. Tulinius, R. Finkel, H. Topaloglu, JW Day, K. Flanigan, et al. "A.06 Ataluren: an overview of clinical trial results in nonsense mutation Duchenne Muscular Dystrophy (nmDMD)." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 43, S2 (June 2016): S8. http://dx.doi.org/10.1017/cjn.2016.58.
Повний текст джерелаMcDonald, Craig M., Francesco Muntoni, Vinay Penematsa, Joel Jiang, Allan Kristensen, Francesco Bibbiani, Elizabeth Goodwin, et al. "Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients." Journal of Comparative Effectiveness Research 11, no. 3 (February 2022): 139–55. http://dx.doi.org/10.2217/cer-2021-0196.
Повний текст джерелаBeryozkin, Avigail, Ananya Samanta, Prakadeeswari Gopalakrishnan, Samer Khateb, Eyal Banin, Dror Sharon, and Kerstin Nagel-Wolfrum. "Translational Read-Through Drugs (TRIDs) Are Able to Restore Protein Expression and Ciliogenesis in Fibroblasts of Patients with Retinitis Pigmentosa Caused by a Premature Termination Codon in FAM161A." International Journal of Molecular Sciences 23, no. 7 (March 24, 2022): 3541. http://dx.doi.org/10.3390/ijms23073541.
Повний текст джерелаRoy, Bijoyita, Westley J. Friesen, Yuki Tomizawa, John D. Leszyk, Jin Zhuo, Briana Johnson, Jumana Dakka, et al. "Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression." Proceedings of the National Academy of Sciences 113, no. 44 (October 4, 2016): 12508–13. http://dx.doi.org/10.1073/pnas.1605336113.
Повний текст джерелаDjayet, Celia, Dominique Bremond-Gignac, Justine Touchard, Philippe-Henri Secretan, Fabrice Vidal, Matthieu P. Robert, Alejandra Daruich, Salvatore Cisternino, and Joël Schlatter. "Formulation and Stability of Ataluren Eye Drop Oily Solution for Aniridia." Pharmaceutics 13, no. 1 (December 22, 2020): 7. http://dx.doi.org/10.3390/pharmaceutics13010007.
Повний текст джерелаRyan, Nicola J. "Ataluren: First Global Approval." Drugs 74, no. 14 (September 2014): 1709–14. http://dx.doi.org/10.1007/s40265-014-0287-4.
Повний текст джерелаCampbell, Craig, Richard J. Barohn, Enrico Bertini, Brigitte Chabrol, Giacomo Pietro Comi, Basil T. Darras, Richard S. Finkel, et al. "Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy." Journal of Comparative Effectiveness Research 9, no. 14 (October 2020): 973–84. http://dx.doi.org/10.2217/cer-2020-0095.
Повний текст джерелаNg, Martin Y., Hong Li, Mikel D. Ghelfi, Yale E. Goldman, and Barry S. Cooperman. "Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms." Proceedings of the National Academy of Sciences 118, no. 2 (January 7, 2021): e2020599118. http://dx.doi.org/10.1073/pnas.2020599118.
Повний текст джерелаGhelfi, Mikel D., Saleem Y. Bhat, Hong Li, and Barry S. Cooperman. "A High-Throughput Assay for In Vitro Determination of Release Factor-Dependent Peptide Release from a Pretermination Complex by Fluorescence Anisotropy—Application to Nonsense Suppressor Screening and Mechanistic Studies." Biomolecules 13, no. 2 (January 27, 2023): 242. http://dx.doi.org/10.3390/biom13020242.
Повний текст джерелаSamanta, Ananya, Katarina Stingl, Susanne Kohl, Jessica Ries, Joshua Linnert, and Kerstin Nagel-Wolfrum. "Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations." International Journal of Molecular Sciences 20, no. 24 (December 12, 2019): 6274. http://dx.doi.org/10.3390/ijms20246274.
Повний текст джерелаGoemans, N., C. Campbell, CM McDonald, T. Voit, X. Luo, G. Elfring, H. Kroger, et al. "D.08 ACT DMD (Ataluren Confirmatory Trial in Duchenne Muscular Dystrophy): effect of Ataluren on timed function tests (TFT) in nonsense mutation (nm) DMD." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 43, S2 (June 2016): S15. http://dx.doi.org/10.1017/cjn.2016.81.
Повний текст джерелаBerger, Joachim, Mei Li, Silke Berger, Michelle Meilak, Jeanette Rientjes, and Peter D. Currie. "Effect of Ataluren on dystrophin mutations." Journal of Cellular and Molecular Medicine 24, no. 12 (April 28, 2020): 6680–89. http://dx.doi.org/10.1111/jcmm.15319.
Повний текст джерелаPeltz, S. W., E. M. Welch, A. Jacobson, C. R. Trotta, N. Naryshkin, H. L. Sweeney, and D. M. Bedwell. "Nonsense suppression activity of PTC124 (ataluren)." Proceedings of the National Academy of Sciences 106, no. 25 (June 8, 2009): E64. http://dx.doi.org/10.1073/pnas.0901936106.
Повний текст джерелаBezzerri, Valentino, Antonio Vella, Elisabetta D'Aversa, Martina Api, Marisole Allegri, Elena Marinelli Busilacchi, Giovanna D'Amico, et al. "Breakthroughs in Preclinical Development of Ataluren (PTC124) As Therapeutic Option for Patients Affected By Shwachman-Diamond Syndrome: Towards the First Clinical Trial." Blood 134, Supplement_1 (November 13, 2019): 451. http://dx.doi.org/10.1182/blood-2019-127866.
Повний текст джерелаPodkletnova, Tatyana V., Lyudmila M. Kuzenkova, Alexey L. Kurenkov, Evgeniya V. Uvakina, Sofya G. Popovich, and Anastasiya A. Lyalina. "A clinical case of successful management of a patient with Duchenne muscular dystrophy caused by a nonsense mutation in the DMD gene." L.O. Badalyan Neurological Journal 3, no. 2 (June 30, 2022): 96–100. http://dx.doi.org/10.46563/2686-8997-2022-3-2-96-100.
Повний текст джерелаMorkous, Sameh S. "Treatment with Ataluren for Duchene Muscular Dystrophy." Pediatric Neurology Briefs 34 (December 4, 2020): 12. http://dx.doi.org/10.15844/pedneurbriefs-34-12.
Повний текст джерелаShoseyov, David, Malena Cohen-Cymberknoh, and Michael Wilschanski. "Ataluren for the treatment of cystic fibrosis." Expert Review of Respiratory Medicine 10, no. 4 (February 24, 2016): 387–91. http://dx.doi.org/10.1586/17476348.2016.1150181.
Повний текст джерелаSiddiqui, Nadeem, and Nahum Sonenberg. "Proposing a mechanism of action for ataluren." Proceedings of the National Academy of Sciences 113, no. 44 (October 19, 2016): 12353–55. http://dx.doi.org/10.1073/pnas.1615548113.
Повний текст джерелаMa, Jiyuan, Nicole Risher, Valerie Northcutt, Young-Choon Moon, Marla Weetall, Ellen Welch, Joseph Colacino, Neil Almstead та Ronald Kong. "Ataluren metabolism: Ataluren-O-1β-acyl glucuronide is a stable circulating metabolite in mouse, rat, dog and human". Drug Metabolism and Pharmacokinetics 38 (червень 2021): 100393. http://dx.doi.org/10.1016/j.dmpk.2021.100393.
Повний текст джерелаMuntoni, Francesco, Isabelle Desguerre, Michela Guglieri, Andrés Nascimento Osorio, Janbernd Kirschner, Már Tulinius, Filippo Buccella, et al. "Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry." Journal of Comparative Effectiveness Research 8, no. 14 (October 2019): 1187–200. http://dx.doi.org/10.2217/cer-2019-0086.
Повний текст джерелаBezzerri, Valentino, Laura Lentini, Martina Api, Elena Marinelli Busilacchi, Vincenzo Cavalieri, Antonella Pomilio, Francesca Diomede, et al. "Novel Translational Read-through–Inducing Drugs as a Therapeutic Option for Shwachman-Diamond Syndrome." Biomedicines 10, no. 4 (April 12, 2022): 886. http://dx.doi.org/10.3390/biomedicines10040886.
Повний текст джерелаMercuri, Eugenio, Ros Quinlivan, and Sylvie Tuffery-Giraud. "Early Diagnosis and Treatment – The Use of Ataluren in the Effective Management of Duchenne Muscular Dystrophy." European Neurological Review 13, no. 1 (2018): 31. http://dx.doi.org/10.17925/enr.2018.13.1.31.
Повний текст джерелаWang, Bingjing, Zhaohui Yang, Becky K. Brisson, Huisheng Feng, Zhiqian Zhang, Ellen M. Welch, Stuart W. Peltz, Elisabeth R. Barton, Robert H. Brown, and H. Lee Sweeney. "Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression." Journal of Applied Physiology 109, no. 3 (September 2010): 901–5. http://dx.doi.org/10.1152/japplphysiol.01366.2009.
Повний текст джерела&NA;. "Ataluren a no nonsense approach to cystic fibrosis." Inpharma Weekly &NA;, no. 1653 (August 2008): 7. http://dx.doi.org/10.2165/00128413-200816530-00011.
Повний текст джерелаPeltz, Stuart W., Manal Morsy, Ellen M. Welch, and Allan Jacobson. "Ataluren as an Agent for Therapeutic Nonsense Suppression." Annual Review of Medicine 64, no. 1 (January 14, 2013): 407–25. http://dx.doi.org/10.1146/annurev-med-120611-144851.
Повний текст джерелаLoudon, John A. "Ataluren: A ‘no-nonsense’ approach for pulmonary diseases." Pulmonary Pharmacology & Therapeutics 26, no. 3 (June 2013): 398–99. http://dx.doi.org/10.1016/j.pupt.2013.01.007.
Повний текст джерелаBushby, Katharine, Richard Finkel, Brenda Wong, Richard Barohn, Craig Campbell, Giacomo P. Comi, Anne M. Connolly, et al. "Ataluren treatment of patients with nonsense mutation dystrophinopathy." Muscle & Nerve 50, no. 4 (September 22, 2014): 477–87. http://dx.doi.org/10.1002/mus.24332.
Повний текст джерелаKong, Ronald, Oscar L. Laskin, Diksha Kaushik, Fengbin Jin, Jiyuan Ma, Joseph McIntosh, Marcio Souza, and Neil Almstead. "Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects." Clinical Pharmacology in Drug Development 8, no. 2 (January 10, 2019): 172–78. http://dx.doi.org/10.1002/cpdd.645.
Повний текст джерелаKent, Emma, and Thomas Paling. "VP16 A NICE Way To Manage Managed Access: Case Study In Muscular Dystrophy." International Journal of Technology Assessment in Health Care 35, S1 (2019): 79. http://dx.doi.org/10.1017/s0266462319002939.
Повний текст джерелаDrake, Kylie M., Benjamin J. Dunmore, Lauren N. McNelly, Nicholas W. Morrell, and Micheala A. Aldred. "Correction of NonsenseBMPR2andSMAD9Mutations by Ataluren in Pulmonary Arterial Hypertension." American Journal of Respiratory Cell and Molecular Biology 49, no. 3 (September 2013): 403–9. http://dx.doi.org/10.1165/rcmb.2013-0100oc.
Повний текст джерелаWilschanski, M., L. L. Miller, D. Shoseyov, H. Blau, J. Rivlin, M. Aviram, M. Cohen, et al. "Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis." European Respiratory Journal 38, no. 1 (January 13, 2011): 59–69. http://dx.doi.org/10.1183/09031936.00120910.
Повний текст джерелаHall, Adam, Lok Wan Liu, Richard Macaulay, and Sean Walsh. "OP127 Sugar And Spice And All Things NICE - Managed Access Agreements." International Journal of Technology Assessment in Health Care 35, S1 (2019): 28–29. http://dx.doi.org/10.1017/s0266462319001582.
Повний текст джерелаLoudon, John A. "Ataluren-time for a 'no–nonsense' approach to haematological malignancies." Hematology and Leukemia 1, no. 1 (2013): 2. http://dx.doi.org/10.7243/2052-434x-1-2.
Повний текст джерелаLoudon, John A. "Ataluren: Time for a ‘No-Nonsense’ Approach to Heart Diseases." Cardiovascular Drugs and Therapy 27, no. 2 (January 6, 2013): 181–82. http://dx.doi.org/10.1007/s10557-012-6435-8.
Повний текст джерелаBlaschek, Astrid, Martin Rodrigues, Lena Ille, Mohammed Idriess, Therese Well, Birgit Warken, Christine Müller, et al. "Is Exercise-Induced Fatigue a Problem in Children with Duchenne Muscular Dystrophy?" Neuropediatrics 51, no. 05 (May 5, 2020): 342–48. http://dx.doi.org/10.1055/s-0040-1708859.
Повний текст джерелаWang, Xia, Xianghong Shan, Kevin Gregory-Evans, and Cheryl Y. Gregory-Evans. "RNA-based therapies in animal models of Leber congenital amaurosis causing blindness." Precision Clinical Medicine 3, no. 2 (March 12, 2020): 113–26. http://dx.doi.org/10.1093/pcmedi/pbaa009.
Повний текст джерелаWerner, C., X. Luo, G. Elfring, H. Kroger, P. Riebling, T. Ong, R. Spiegel, and S. Peltz. "Meta-analyses of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy." Neuropediatrics 48, S 01 (April 26, 2017): S1—S45. http://dx.doi.org/10.1055/s-0037-1602954.
Повний текст джерелаMuntoni, F., E. Mercuri, X. Luo, G. Elfring, C. Werner, P. Trifillis, S. W. Peltz, and C. M. McDonald. "Meta-analyses of ataluren in patients with nonsense mutation Duchenne muscular dystrophy." Neuromuscular Disorders 28 (April 2018): S12. http://dx.doi.org/10.1016/s0960-8966(18)30323-7.
Повний текст джерелаZainal Abidin, Noreen, Iram J. Haq, Aaron I. Gardner, and Malcolm Brodlie. "Ataluren in cystic fibrosis: development, clinical studies and where are we now?" Expert Opinion on Pharmacotherapy 18, no. 13 (August 1, 2017): 1363–71. http://dx.doi.org/10.1080/14656566.2017.1359255.
Повний текст джерелаSeo, K., D. Kim, H. Lee, and J. Shin. "FP.33 Ataluren treatment in 30-week-old dysferlinopathy mouse with nonsense mutation." Neuromuscular Disorders 32 (October 2022): S112. http://dx.doi.org/10.1016/j.nmd.2022.07.293.
Повний текст джерелаBhattacharya, Arpan, Shijie Huang, Mikel D. Ghelfi, Hong Li, Clark Fritsch, David M. Chenoweth, Barry S. Cooperman, and Yale E. Goldman. "Elucidating the mechanism and target sites of ataluren inside the protein synthesis machinery." Biophysical Journal 121, no. 3 (February 2022): 203a. http://dx.doi.org/10.1016/j.bpj.2021.11.1723.
Повний текст джерелаReeves, Emer P., Ciara A. O’Dwyer, Danielle M. Dunlea, Mark R. Wormald, Padraig Hawkins, Mohammad Alfares, Darrell N. Kotton, Steven M. Rowe, Andrew A. Wilson, and Noel G. McElvaney. "Ataluren, a New Therapeutic for Alpha-1 Antitrypsin–Deficient Individuals with Nonsense Mutations." American Journal of Respiratory and Critical Care Medicine 198, no. 8 (October 15, 2018): 1099–102. http://dx.doi.org/10.1164/rccm.201802-0338le.
Повний текст джерелаWalsh, Sean, Ricky Tsang, Erika Turkstra, and Richard Macaulay. "VP22 Future Trends For Managed Access Agreements In The UK." International Journal of Technology Assessment in Health Care 34, S1 (2018): 164–65. http://dx.doi.org/10.1017/s0266462318003446.
Повний текст джерелаMartínez-Edo, Gabriel, Maria C. Llinàs, Salvador Borrós, and David Sánchez-García. "Isothiocyanate-Functionalized Mesoporous Silica Nanoparticles as Building Blocks for the Design of Nanovehicles with Optimized Drug Release Profile." Nanomaterials 9, no. 9 (August 29, 2019): 1219. http://dx.doi.org/10.3390/nano9091219.
Повний текст джерелаTutone, Marco, Ivana Pibiri, Laura Lentini, Andrea Pace, and Anna Maria Almerico. "Deciphering the Nonsense Readthrough Mechanism of Action of Ataluren: An in Silico Compared Study." ACS Medicinal Chemistry Letters 10, no. 4 (February 7, 2019): 522–27. http://dx.doi.org/10.1021/acsmedchemlett.8b00558.
Повний текст джерелаDe Boeck, K., H. G. M. Heijerman, J. C. Davies, I. Sermet-Gaudelus, L. Hjelte, E. Kerem, J. Sun, J. Mcintosh, A. Malfroot, and H. A. W. M. Tiddens. "WS13.1 Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin." Journal of Cystic Fibrosis 15 (June 2016): S20—S21. http://dx.doi.org/10.1016/s1569-1993(16)30132-1.
Повний текст джерела